Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

p38 but not p53 is responsible for UVA-induced MCPIP1 expression

(2018) Lukasz Skalniak et al.   MECHANISMS OF AGEING AND DEVELOPMENT

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

(2018) Luis A. Carvajal et al.   Science Translational Medicine

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

(2017) Audrey Laroche-Clary et al.   Journal of Hematology & Oncology

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

(2017) Veronica Tisato et al.   Journal of Hematology & Oncology

ClinVar: improving access to variant interpretations and supporting evidence

(2017) Melissa J Landrum et al.   NUCLEIC ACIDS RESEARCH

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/−mouse model

(2017) Emilie A. Chapeau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

(2017) Maryam Zanjirband et al.   Oncotarget

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

(2017) Viktor Arnhold et al.   Oncotarget

MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas

(2017) Audrey Laroche et al.   Oncotarget

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

(2017) Alan Van Goethem et al.   Oncotarget

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

(2016) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)

(2016) Frank Herting et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

(2016) Christian Lehmann et al.   Journal of Hematology & Oncology

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner

(2016) A. Esfandiari et al.   MOLECULAR CANCER THERAPEUTICS

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program

(2016) Min H. Kang et al.   PEDIATRIC BLOOD & CANCER

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

(2016) Joonil Jung et al.   Nature Communications

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

(2016) Catherine J. Drummond et al.   Oncotarget

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo

(2015) C. G. Hoffman-Luca et al.   CLINICAL CANCER RESEARCH

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

(2015) Philipp Holzer et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma

(2015) Doris Phelps et al.   PEDIATRIC BLOOD & CANCER

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

(2015) Lindi Chen et al.   Oncotarget

An automated fitting procedure and software for dose-response curves with multiphasic features

(2015) Giovanni Y. Di Veroli et al.   Scientific Reports

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

(2015) Sébastien Jeay et al.   eLife

SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression

(2014) S. Wang et al.   CANCER RESEARCH

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

(2014) Mariko Yoshimura et al.   CANCER SCIENCE

Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation

(2014) Ramiro París et al.   CELL CYCLE

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

(2014) Daqing Sun et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction

(2014) Ana Z. Gonzalez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition

(2014) Siau Jia Wei et al.   PLoS One

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis

(2012) Bernard Leroy et al.   NUCLEIC ACIDS RESEARCH

SIFT web server: predicting effects of amino acid substitutions on proteins

(2012) Ngak-Leng Sim et al.   NUCLEIC ACIDS RESEARCH

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

(2011) M H Aziz et al.   ONCOGENE

Two-phase dynamics of p53 in the DNA damage response

(2011) X.-P. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

(2011) M Michaelis et al.   Cell Death & Disease

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

p53 at a glance

(2010) C. A. Brady et al.   JOURNAL OF CELL SCIENCE

Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells

(2009) B. Huang et al.   MOLECULAR CANCER RESEARCH

MCF-7 breast carcinoma cells do not express caspase-3

(2008) Reiner U. Jänicke   BREAST CANCER RESEARCH AND TREATMENT